Skip to content
1st Counsel – Lifestyle
Author:
Antengene Corporation Limited
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
June 9, 2026
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
June 7, 2026
Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
June 3, 2026